Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$11.28 USD
-0.55 (-4.65%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.29 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RNAC 11.28 -0.55(-4.65%)
Will RNAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
Other News for RNAC
Cartesian Therapeutics (RNAC) Grants Stock Options to New Employees
Cartesian Therapeutics announces new employment inducement grants
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News
Cartesian: Autoimmune Cell Therapy Excites, But Reality Bites
RNAC: Wedbush Foresees Promising Future for Cartesian Therapeutics | RNAC Stock News